WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in China, has announced a significant expansion of its manufacturing capacity at the facility located in Worcester, Massachusetts. The total manufacturing capacity at the site is set to increase to 36,000 liters, marking a substantial upgrade from the initially planned 24,000 liters.
The enhancement includes an additional 12,000 liters of commercial drug substance capacity, which will significantly bolster the facility’s production capabilities. Construction of the expansive 189,500-square-foot facility is currently in progress and has recently reached the weather tight milestone. The facility is expected to become operational in 2025, with the aim of achieving Good Manufacturing Practice (GMP) certification by 2026, indicating readiness for commercial production.
This expansion underscores WuXi Biologics’ commitment to enhancing its global footprint and meeting the growing demand for biopharmaceutical manufacturing services.- Flcube.com
